Research and Development :: Pharmaceuticals

Pharma Industry / Biotech Industry News From Medical News Today

Gilead's Antiretroviral Patent Request Rejected By Brazil
Fri, 05 Sep 2008 11:00:00 -0700
A patent request from the pharmaceutical company Gilead for its antiretroviral drug tenofovir was rejected by Brazil Wednesday, Reuters reports. After announcing the decision, a
BioCryst Reports Results From BCX-4208 Phase IIa Trial In Subjects With Psoriasis
Fri, 05 Sep 2008 04:00:00 -0700
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced results from the completed Phase IIa trial of BCX-4208 in patients with moderate to severe plaque psoriasis. Consistent with interim findings reported in May 2008, this study of BCX-4208, a potent, rationally designed, orally available purine nucleoside phosphorylase (PNP) inhibitor, met its primary objectives of safety and tolerability.
Agile Therapeutics Achieves Phase 2 Study Endpoints In Key Clinical Trials With New, Innovative Low-Dose Contraceptive Patch
Fri, 05 Sep 2008 04:00:00 -0700
Agile Therapeutics, Inc., announced that it successfully completed two key clinical trials in the development of the company's new, innovative low-dose, once-weekly, contraceptive patch, which the company refers to by its internal product code AG-200-15. The Phase 2b safety and efficacy study successfully met its primary endpoint of ovulation suppression, cycle control and safety.
Cystic Fibrosis Axentis Pharma Initiates Clinical Trial For Lung Infections
Fri, 05 Sep 2008 04:00:00 -0700
Axentis Pharma AG has initiated a clinical phase IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treatment of severe pulmonary infection in cystic fibrosis patients. The new formulation allows an established therapeutic agent to be delivered directly to the site of infection. The forthcoming trial will also compare the effects of two different doses of the new drug. Initial results are expected in summer 2009.
QuatRx Initiates Second Phase 3 Study Of Ophena(TM) (Ospemifene Tablets) In Women With Postmenopausal Vaginal Syndrome
Fri, 05 Sep 2008 04:00:00 -0700
QuatRx Pharmaceuticals, a privately-held biopharmaceutical company focused on development and commercialization of compounds to treat endocrine, metabolic and cardiovascular disorders, announced that it has initiated a second Phase 3 clinical trial of Ophena(TM) (ospemifene tablets), the company's estrogen-free oral therapy in development for the treatment of vaginal symptoms associated with menopause.
Bilcare GCS Expands Phase III Clinical Trial Service Capabilities
Fri, 05 Sep 2008 04:00:00 -0700
As part of its commitment to providing its customers with comprehensive services that span the entire clinical supply chain, Bilcare Global Clinical Supplies, a leading single-source provider of clinical trial supplies and services, has enhanced its global Phase III capabilities.  Its latest Phase III investments include the upgrade of its Kalish large-scale bottling line at its U.S.

The Seattle Times: Biotech


News on biotechnology pharmaceutical from BioPortfolio.com

High Growth Forecasted for the In Vitro Diagnostics Market Report and Analysis 2008-2023
Interest!ALERT:
RNCOS Releases a New Report- Asia Pacific Biotechnology Market (2008-2012)
24-7PressRelease.com:
Quinnova Pharmaceuticals, Inc
BioSpace:

The Economist: Biotechnology

Pharmaceuticals: Convergence or conflict?
Thu, 28 Aug 2008 11:35:36 -0000
Drug giants’ recent attempts to buy big biotech firms have provoked a backlashDALLIANCES between conventional pharmaceutical companies and biotechnology firms are nothing new. Big Pharma, eager to refill its emptying drug pipelines, has in recent years looked hopefully to biotech’s upstarts. The drugs giants have pursued all sorts of tie-ups, from alliances to licensing deals to outright purchases of a few smallish companies. But mindful of the sharp cultural differences between the two sorts of firms, they have generally avoided big acquisitions.Until now, that is. In recent weeks Roche, a Swiss pharmaceuticals giant, has made a surprise $44 billion bid for the 44% of Genentech, the world’s biggest biotech firm by stockmarket value, that it does not already own; and Bristol-Myers Squibb (BMS), an American drugs company, has offered $4.5 billion for the 83% of ImClone, an American biotech firm, that it does not already control. These attempts came on the heels of earlier deals in which AstraZeneca, a British drugs giant, bought MedImmune for $15.6 billion, and Takeda of Japan paid $8.8 billion for Millennium. ...
Gene doping: Fairly safe
Thu, 31 Jul 2008 12:10:21 -0000
What athletes may or may not do ought to be decided on grounds of safety, not fairnessANOTHER Olympics, another doping debate. And this time it is a fervent one, as recent advances in medical science have had the side-effect of providing athletes with new ways of enhancing performance, and thus of putting an even greater strain on people’s ethical sensibilities. This is especially true of gene therapy. Replacing defective genes holds out great promise for people suffering from diseases such as muscular dystrophy and cancer. But administered to sprightly sportsmen, the treatment may allow them to heave greater weights, swim faster and jump farther (see article). And that would be cheating, wouldn’t it? ...
Gene doping: Genetically Modified Olympians?
Thu, 31 Jul 2008 12:10:21 -0000
On the eve of the Beijing Olympics, we examine the prospect of athletes using gene therapy to enhance their performance—and of catching them if they tryFOR as long as people have vied for sporting glory, they have also sought shortcuts to the champion’s rostrum. Often, those shortcuts have relied on the assistance of doctors. After all, most doping involves little more than applying existing therapies to healthy bodies. These days, however, the competition is so intense that existing therapies are not enough. Now, athletes in search of the physiological enhancement they need to take them a stride ahead of their opponents are scanning medicine’s future, as well as its present. In particular, they are interested in a field known as gene therapy. Gene therapy works by inserting extra copies of particular genes into the body. These extra copies, known as “transgenes”, may cover for a broken gene or regulate gene activity. Though gene therapy has yet to yield a reliable medical treatment, more than 1,300 clinical trials are now under way. As that number suggests, the field is reckoned to be full of promise. ...

 

Subscribe to Biotechnology_and_Pharmaceuticals RSS feed

Aphton Corp. - Develops products using vaccine-like technology for neutralizing hormones which participate in gastrointestinal system and reproductive system cancer and non-cancer diseases and the prevention of pregnancy. Based in Miami, Florida. (Nasdaq: APHT)

Archemix Corp. - Company developing therapeutics of aptamers, for the prevention and treatment of chronic and acute disease. Includes overview of technology and commercial potential, careers and contacts in Cambridge, Massachusetts.
Meta Description: [ Archemix is the biopharmaceutical company leading the development of aptamers as a new class of directed therapeutics for the prevention and treatment of chronic and acute disease. Aptamer Therapeutics ]

Arena Pharmaceuticals, Inc. - Receptor-based drug discovery in the fields of diabetes, obesity, cardiovascular, sleep disorders, neurodegeneration, schizophrenia, depression and anxiety. Comprehensive profile of company in San Diego, California. (Nasdaq: ARNA)

500 AusAm Biotechnologies, Inc. - Developing diagnostics and drugs from core discoveries in protein and polysaccharide chemistry, including anti-viral attachment inhibitors. Includes research overview, distributors, and offices in Chicago and Santa Monica, California.
Meta Description: [ Hostway Corporation offers webhosting, e-commerce hosting, dedicated servers and domain name registrations for individuals, small businesses and large enterprises. Hostway Corporation provides Web hosting and managed services to more than 300,000 customers worldwide offering user-easy and afforda... ]

AVI Biopharma, Inc. - Develops and commercializes a vaccine against human chorionic gonadotropin secreting cancers, and synthetic antisense technology to inhibit translation in treating cardiovascular, kidney and viral diseases. Research and manufacturing facilities in Corvallis, Oregon. (Nasdaq: AVII)
Meta Description: [ AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using two technology platforms: third generation NeuGene(tm) antisense drugs and cancer immunotherapy. ]

Avigen, Inc. - Develops gene-based therapeutic products derived from adeno-associated virus for the treatment of inherited and acquired diseases. Includes explanation of technology, product pipeline, collaborative partnerships and investment data, from manufacturing facility in Alameda, California. (Nasdaq: AVGN)

BioMep Inc. - Company founded in 1997 to develop new therapies for bone diseases. Outlines products under development and news from Montreal, Canada.
Meta Description: [ cellular accessories cell phone deals download ringtones video games gift ]

BioSphings AG. - Development and marketing of products to treat viral infections, cancer and autoimmune diseases. Features product pipeline and company details. Frankfurt, Germany.
Meta Description: [ BioSphings, a biopharmaceutical company based in Frankfurt, Germany, focuses on the development of novel therapeutic approaches for the treatment of cancer, autoimmune diseases and viral infections. ]

Cue Biotech Inc. - Company focusing on G-protein coupled receptor signaling as targets for therapeutic products. Includes corporate data, partnering and technology overviews, with media resources, list of publications, and opportunities in Chicago, Illinois.
Meta Description: [ Cue BIOtech is a drug discovery company focused on bringing to market a portfolio of advanced therapeutics that target G Protein Coupled Receptors (GPCRs). ]

Curis, Inc - Developing small molecule and peptide drugs in regulatory signaling and regenerative pathways. Introduces technical background, product pipeline, collaborations, investment data and careers headquartered from Cambridge, Massachusetts. (Nasdaq: CVGP)
Meta Description: [ Curis is a therapeutic drug development company, focusing on regulatory pathways that control repair and regeneration using proteins or small molecules to modulate these pathways. ]

Cyano Biotech GmbH. - Identifies and characterises structural variants of polyketides and non-ribosomal cyclic heptapeptides from cyanobacteria, and optimises pharmacological activity using biocombinatorial techniques. Profile, collaborators and contacts in Germany.
Meta Description: [ Cyano Biotech identifies and characterises natural products by screening cyanobacteria and optimises bioactive compounds regarding harmacological needs employing combinatorial biosynthesis generating novel lead compounds for the pharma industry. ]

500 Endocube - Engaged in the identification, validation and selection of novel drugable targets and product candidates for the diagnosis and treatment of chronic inflammatory diseases. Profiles of technology, product pipeline and corporation in Labege, France.

EntreMed, Inc. - Researches and develops biopharmaceutical products which address the role of blood and blood vessels in the prevention and treatment of diseases by inhibiting growth or enhancing bioavailability of drugs. Based in Rockville, Maryland. (Nasdaq: ENMD)
Meta Description: [ EntreMed, Inc. is a clinical-stage pharmaceutical company focused on developing the next generation of multi-mechanism oncology and anti-inflammatory drugs that target disease cells directly and the blood vessels that nourish them. EntreMed is focused on developing drugs that are safe and conveni... ]

Gemac - Researching diagnostics and drug candidates for the treatment of amyotrophic lateral and multiple sclerosis, as well as autoimmune diseases, including anti-idiotypic antibodies. Includes overview of corporation in Cenon, France.

Genelabs Technologies, Inc. - Discovers, develops and commercializes therapies for systemic lupus erythematosus, viral diseases and cancer. Located in Redwood City, California.(Nasdaq: GNLB)
Meta Description: [ Genelabs Technologies, Inc. is a global biopharmaceutical and diagnostics company focused on gene-regulating drug discovery; infectious diseases including hepatitis; and immunological disorders including lupus. ]

Genentech, Inc. - Genetic engineering techniques in the discovery, development, production, and marketing of human therapeutics. Includes research history, product pipline, global corporate and career information, from South San Francisco, California.
Meta Description: [ Genentech Inc., the founder of the biotechnology industry, is a pioneer in biotechnology research and is a leading biotechnology company. It discovers, develops, manufactures and markets biopharmaceuticals for significant unmet medical needs. ]

Genfit - Researching nuclear receptors and gene deregulation for treatment of cardiovascular, metabolic and inflammatory diseases. Includes information about genomic research headquartered in Loos, France.
Meta Description: [ Biopharmaceutical company studying nuclear receptors, gene deregulation and dedicated to find treatments to cardiovascular diseases, metabolic diseases and inflammatory diseases. Features informations about genomic research and drug dicovery ]

Hemobiotech Inc. - Developer of blood substitute, aiming to address intrinsic hemoglobin toxicity. Introduction to company and their work, with form to contact Dallas, Texas.

500 Hybridon, Inc. - Engaged in the discovery and development of novel therapeutics and diagnostics using synthetic DNA and antisense technology. Based in Cambridge, Massachusetts. (AMEX: HBY)

Imclone Systems Inc. - Researches and develops growth factor blockers and anti-cancer vaccines. Includes clinical programs, investor details and overview of company in New York City. (Nasdaq: IMCL)

Intra-Cellular Therapies, Inc. - Developing novel drugs against targets inside nerve cells to treat CNS disorders. Includes therapeutic projects, target biochemistry, corporate data and contacts for headquarters in New York City.
Meta Description: [ Intracellular Therapies, Inc. (ITI) is developing novel drugs for the treatment of depression, schizophrenia, Parkinson1s and Alzheimer1s disease and other Central Nervous System (CNS) disorders, based on proprietary targets identified and validated in vivo. ]

Intrabiotics Pharmaceuticals, Inc. - Develops antibacterial and antifungal drugs, including protegrins and related antimicrobial peptides, for application in cystic fibrosis. Includes pipeline, publications, and investor information from Palo Alto, California. (Nasdaq: IBPI)

MannKind Corp. - Developing a pulmonary insulin delivery system, and immunotherapy of cancer, by identifying tumor-related antigens, DNA and peptide-based drugs evoking cell-mediated responses. Located in Valencia, California.
Meta Description: [ MannKind' s Website ]

Maxygen, Inc. - Develops proprietary protein modifications including PEG, glycosylation and vaccines. Overview of technologies, clinical trial pipeline, investor data and careers in Redwood City, California. (Nasdaq: MAXY)

Mixture Sciences, Inc. - A privately held company that specializes in research for treatment of cancer, diabetes, multiple sclerosis, HIV/AIDS and infectious diseases, including Lyme Disease. Lists research projects and procedures. Based in San Diego, California.
Meta Description: [ Mixture Sciences, Inc., a privately-held biotechnology company, specializes in biomedical research and drug discovery. ]

Nephros Therapeutics, Inc. - Specialist in the design, development, and marketing of human cell replacement therapy systems, targeting inflammatory disease. Includes directions to research labs at Ann Arbor, Michigan, and corporate offices in Lincoln, Rhode Island.
Meta Description: [ 1000s of businesses for sale on the Internet's largest business for sale exchange. Sell a business for sale with a confidential ad or use a business broker., Businesses for sale. Buy a business for sale from our directory of business sales. Sell a business for sale with a confidential ad or use a... ]

Novacta Biosystems Ltd. - Drug discovery and development company using pathway engineering and chemistry to optimise the activity of natural products for the treatment of infectious diseases. Introduces biotransformation technology, lead compounds, key personnel in Hatfield, England.

Nymox Pharmaceutical Corp. - Researches and develops neurological diagnostics and pharmaceuticals for the aging population with emphasis on Alzheimer's disease. Profile of company with bases in Maywood, New Jersey and Saint Laurent, Quebec. (Nasdaq: NYMX)
Meta Description: [ Nymox is a development stage biopharmaceuticals company based in Maywood, NJ and St. Laurent, Quebec. Nymox specializes in the research and development of therapeutics and diagnostics for the aging population with an emphasis on Alzheimer's disease. ]

Optimer Pharmaceuticals - Develops late-stage anti-infective and preclinical antibiotics by carbohydrate technology.
Meta Description: [ Optimer's core competence includes the development of innovative drugs for treating diseases that currently have no satisfactory therapy. These include antibiotics for drug-resistant bacterial infections, a cancer vaccine, and ]

Praecis Pharmaceuticals Inc. - Develops peptide-based therapeutics for the treatment of human hormone diseases, prostate cancer endometriosis, and inflammatory diseases. Includes therapeutic targets and profile of facilities in Waltham, Massachusetts. (Nasdaq: PRCS)
Meta Description: [ GSK.com is the corporate web site of GlaxoSmithKline, a leading healthcare company that helps people to do more, feel better and live longer. Find out how GlaxoSmithKline improves health and quality of life. Discover GlaxoSmithKline's research and development, community partnerships and public he... ]

Rib-X Pharmaceuticals Inc. - Structure-based drug design start-up, specializing in the ribosome as a target, and bacterial antibiotic resistance. Includes mechanisms of action, glossary, careers, corporate news and contacts and directions in New Haven, Connecticut.

Sierra Sciences Inc. - Developing drugs and therapies to reverse the effects of human aging by focusing on preserving the length of telomeres, to keep them more resilient. Careers in Reno, Nevada.
Meta Description: [ Sierra Sciences, LLC. is developing drugs and therapies to reverse the effects of human aging. Our near-term goal is to develop a drug that will temporarily activate telomerase expression and re-lengthen telomeres of aging human cells. ]

Synaptic Pharmaceutical Corp. - Applies human receptor-targeted drug design technology to discover and clone genes and to design G protein-coupled receptor agonist and antagonists. Based in Paramus, New Jersey. (Nasdaq: SNAP)
Meta Description: [ Welcome to the homepage of H. Lundbeck A/S ]

Trophogen, Inc - Development of superactive hormones and growth factors for therapeutic applications. Based in Rockville, Maryland, USA.
Meta Description: [ Trophogen, Inc. is a biotechnology company founded in 2001, focusing on the development of high affinity glycoprotein hormone and related growth factor analogs for targeted therapy and imaging of ovarian, breast, prostate, testicular and thyroid cancers as well as for human and animal infertility. ]

Voyager Pharmaceutical Corp. - Specializes in age-related diseases. Includes patient links for Alzheimer's Disease, clinical trials, company news and careers in Raleigh, North Carolina.
Meta Description: [ Voyager Pharmaceutical Corporation is rapidly to bringing to market a patented treatment that stops the progression of Alzheimer's. Our focus is finding cures for Alzheimer's and other aging diseases ]

Xencor, Inc. - Technology for MHC epitope removal, glycosylation to optimize pharmacokinetics, masking immune recognition sites and engineering monoclonal antibodies. Includes discovery programs, partnering opportunities in Monrovia, California. ImmunoPDA™ Technology Product Sheet Caltech spin-off developing proteomic technologies to accelerate drug discovery.

Xenova Group plc - Holding company for drug discovery subsidiaries, developing anti-cancer compounds in clinical stage, and addiction vaccines. Includes candidates for therapeutic focus, investor details, with contacts in Slough and Cambridge, England. (Nasdaq: XNVA)

Xoma - Development and manufacture of recombinant proteins and peptides, in partnership with big pharmas. Includes licensing of technology derived from the host-defense protein BPI, monoclonal antibodies to treat chemotherapy-induced thrombocytopenia, and to target cancer. Based in Berkeley, California.

ZymoGenetics, Inc. - Discovery, development and commercialization of therapeutic proteins for the prevention and treatment of human diseases. Includes product pipeline, news on clinical trials and profile of company in Seattle, Washington.
Meta Description: [ ZymoGenetics targets promising protein therapies. ]